Home LiteratureArticle Details
PMID: 16524427 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review

NF-kappaB activation in melanoma.

Pigment cell research ·Vol. 19 ·No. 2 ·2006-04-00 ·Pages 112-24

Ueda Y, Richmond A

Abstract

Metastatic melanoma is an aggressive skin cancer that is notoriously resistant to current cancer therapies. In human melanoma, nuclear factor-kappa B (NF-kappaB) is upregulated, leading to the deregulation of gene transcription. In this review, we discuss (i) the relationship between gene alteration in melanoma and upregulation of NF-kappaB, (ii) mechanisms by which activated NF-kappaB switch from pro-apoptotic to anti-apoptotic functions in melanoma and (iii) autocrine mechanisms that promote constitutive activation of NF-kappaB in metastatic melanoma.

MeSH Terms
Animals Autocrine Communication Gene Expression Regulation, Neoplastic Humans Melanoma/metabolism,pathology NF-kappa B/biosynthesis Neoplasm Metastasis/pathology Skin Neoplasms/metabolism,pathology Transcription, Genetic Up-Regulation
Chemicals
NF-kappa B
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Ueda Yukiko
Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Richmond Ann
References (180)
180 references, click to expand
  1. Common structural constituents confer I kappa B activity to NF-kappa B p105 and I kappa B/MAD-3.
    EMBO J. 1993 Jul;12(7):2781-8 PMID: 8334994
  2. Shc products are substrates of erbB-2 kinase.
    Oncogene. 1993 Aug;8(8):2105-12 PMID: 8101647
  3. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop.
    Mol Cell Biol. 1993 Oct;13(10):6231-40 PMID: 8413223
  4. Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages.
    Nat Cell Biol. 1999 May;1(1):69-71 PMID: 10559867
  5. Genes involved in melanoma: an overview of INK4a and other loci.
    Melanoma Res. 1999 Oct;9(5):421-32 PMID: 10596908
  6. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.
    Clin Cancer Res. 2000 May;6(5):1845-53 PMID: 10815907
  7. Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling.
    Biochem Biophys Res Commun. 2000 Jun 16;272(3):856-63 PMID: 10860842
  8. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis.
    J Clin Invest. 2000 Jun;105(12):1799-806 PMID: 10862795
  9. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice.
    Clin Cancer Res. 2000 Jun;6(6):2573-81 PMID: 10873114
  10. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression.
    Oncogene. 2000 Jun 15;19(26):3003-12 PMID: 10871852
  11. Signal transduction by CXC chemokine receptor 4. Stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes.
    J Exp Med. 2000 Aug 7;192(3):313-24 PMID: 10934220
  12. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity.
    Cytokines Cell Mol Ther. 2000 Mar;6(1):9-17 PMID: 10976534
  13. Identification of PTEN mutations in metastatic melanoma specimens.
    J Med Genet. 2000 Sep;37(9):653-7 PMID: 10978354
  14. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
    Am J Pathol. 2000 Oct;157(4):1123-8 PMID: 11021816
  15. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types.
    FEBS Lett. 2000 Oct 6;482(3):193-9 PMID: 11024459
  16. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies.
    J Immunol. 2000 Nov 1;165(9):5084-96 PMID: 11046039
  17. New developments in melanoma genetics.
    Curr Oncol Rep. 2000 Jul;2(4):300-6 PMID: 11122857
  18. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases.
    Br J Cancer. 2001 Jan 5;84(1):72-9 PMID: 11139316
  19. Involvement of chemokine receptors in breast cancer metastasis.
    Nature. 2001 Mar 1;410(6824):50-6 PMID: 11242036
  20. p16(MTS-1/CDKN2/INK4a) in cancer progression.
    Exp Cell Res. 2001 Mar 10;264(1):42-55 PMID: 11237522
  21. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8.
    Int J Cancer. 2003 Jan 20;103(3):335-43 PMID: 12471616
  22. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation.
    J Biol Chem. 2002 Dec 20;277(51):49212-9 PMID: 12370187
  23. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression.
    Cancer Res. 2002 Dec 15;62(24):7335-42 PMID: 12499277
  24. Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi.
    J Med Genet. 2003 Feb;40(2):E14 PMID: 12566532
  25. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
    Br J Cancer. 2003 Jan 27;88(2):175-80 PMID: 12610499
  26. Endogenous association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a novel mechanism of apoptosis.
    J Biol Chem. 2003 Apr 18;278(16):14363-9 PMID: 12571250
  27. Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination.
    J Biol Chem. 2003 Apr 18;278(16):14498-506 PMID: 12574160
  28. Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors.
    J Endotoxin Res. 2003;9(1):55-9 PMID: 12691620
  29. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data.
    Pigment Cell Res. 2003 Jun;16(3):297-306 PMID: 12753404
  30. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival.
    J Gen Virol. 2004 May;85(Pt 5):1065-76 PMID: 15105524
  31. Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway.
    Oncogene. 2004 May 6;23(21):3883-7 PMID: 15021910
  32. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Cancer Res. 2004 May 15;64(10):3428-35 PMID: 15150094
  33. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Cancer Res. 1996 Dec 1;56(23):5475-83 PMID: 8968104
  34. A conserved signaling pathway: the Drosophila toll-dorsal pathway.
    Annu Rev Cell Dev Biol. 1996;12:393-416 PMID: 8970732
  35. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1.
    Nature. 1997 Feb 6;385(6616):540-4 PMID: 9020361
  36. Mitogen-activated protein kinase pathways.
    Curr Opin Cell Biol. 1997 Apr;9(2):180-6 PMID: 9069255
  37. Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes.
    Blood. 1997 Jun 15;89(12):4461-9 PMID: 9192770
  38. Identification and characterization of an IkappaB kinase.
    Cell. 1997 Jul 25;90(2):373-83 PMID: 9244310
  39. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions.
    FEBS Lett. 1997 Jun 23;410(1):83-6 PMID: 9247128
  40. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.
    Science. 1997 Oct 31;278(5339):866-9 PMID: 9346485
  41. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression.
    J Leukoc Biol. 1997 Nov;62(5):588-97 PMID: 9365113
  42. The dysplastic naevus.
    J Clin Pathol. 1997 Sep;50(9):711-5 PMID: 9389970
  43. The many faces of G protein signaling.
    J Biol Chem. 1998 Jan 9;273(2):669-72 PMID: 9422713
  44. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture.
    J Exp Med. 1998 Jan 19;187(2):147-59 PMID: 9432973
  45. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses.
    J Exp Med. 1998 Jan 19;187(2):185-96 PMID: 9432976
  46. Specificity within the EGF family/ErbB receptor family signaling network.
    Bioessays. 1998 Jan;20(1):41-8 PMID: 9504046
  47. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases.
    EMBO J. 1998 Apr 15;17(8):2215-23 PMID: 9545235
  48. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways.
    J Biol Chem. 1998 Sep 4;273(36):23169-75 PMID: 9722546
  49. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways.
    Mol Cell. 1998 Aug;2(2):253-8 PMID: 9734363
  50. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
    Science. 1998 Sep 11;281(5383):1680-3 PMID: 9733516
  51. The p16INK4a/CDKN2A tumor suppressor and its relatives.
    Biochim Biophys Acta. 1998 Oct 14;1378(2):F115-77 PMID: 9823374
  52. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment.
    Mol Cell Biol. 1999 Mar;19(3):2098-108 PMID: 10022897
  53. Role of epidermal growth factor receptor signaling in RAS-driven melanoma.
    Mol Cell Biol. 2005 May;25(10):4176-88 PMID: 15870287
  54. Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations.
    Biochem Biophys Res Commun. 2005 Jul 8;332(3):873-9 PMID: 15913553
  55. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
    Br J Cancer. 2005 Jun 6;92(11):2032-8 PMID: 15928660
  56. Negative regulation of toll-like receptor-mediated immune responses.
    Nat Rev Immunol. 2005 Jun;5(6):446-58 PMID: 15928677
  57. The adaptor protein TRADD activates distinct mechanisms of apoptosis from the nucleus and the cytoplasm.
    Cell Death Differ. 2005 May;12(5):473-81 PMID: 15761471
  58. Differential expression of chemokines in synovial cells exposed to different Borrelia burgdorferi isolates.
    Clin Exp Rheumatol. 2005 May-Jun;23(3):311-22 PMID: 15971418
  59. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
    Carcinogenesis. 2005 Jul;26(7):1224-32 PMID: 15760917
  60. BRAFE600-associated senescence-like cell cycle arrest of human naevi.
    Nature. 2005 Aug 4;436(7051):720-4 PMID: 16079850
  61. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
    Cancer. 2005 Aug 15;104(4):879-90 PMID: 16007726
  62. Epidermal growth factor activates nuclear factor-kappaB in human proximal tubule cells.
    Am J Physiol Renal Physiol. 2005 Oct;289(4):F808-15 PMID: 15798085
  63. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15 PMID: 16234564
  64. TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells.
    Mol Cell Biol. 2005 Nov;25(22):9806-19 PMID: 16260598
  65. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma.
    Melanoma Res. 2005 Dec;15(6):515-22 PMID: 16314737
  66. MAP kinase activation is required for the MMP-9 induction by TNF-stimulation.
    Arch Pharm Res. 2005 Nov;28(11):1257-62 PMID: 16350852
  67. Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis.
    J Biol Chem. 2006 Jan 20;281(3):1840-52 PMID: 16306044
  68. The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-kappaB through TRAF6 and TAK1.
    J Biol Chem. 2006 Jan 27;281(4):2162-9 PMID: 16280329
  69. Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4.
    Cancer Lett. 2006 Apr 8;235(1):75-83 PMID: 15922507
  70. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
    Cancer Res. 2005 Aug 1;65(15):6601-11 PMID: 16061640
  71. The INK4A/ARF locus and its two gene products.
    Curr Opin Genet Dev. 1999 Feb;9(1):22-30 PMID: 10072356
  72. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2994-9 PMID: 10077625
  73. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition.
    Mol Cell Biol. 1999 Apr;19(4):2690-8 PMID: 10082535
  74. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice.
    Br J Cancer. 1999 Mar;79(7-8):1025-31 PMID: 10098731
  75. The pathogenesis of melanoma induced by ultraviolet radiation.
    N Engl J Med. 1999 Apr 29;340(17):1341-8 PMID: 10219070
  76. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.
    Genes Dev. 1999 Apr 15;13(8):1015-24 PMID: 10215628
  77. Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways.
    J Biol Chem. 1999 May 14;274(20):13841-6 PMID: 10318790
  78. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.
    Mol Cell. 2001 Feb;7(2):401-9 PMID: 11239468
  79. Chemokines: not just leukocyte chemoattractants in the promotion of cancer.
    Nat Immunol. 2001 Apr;2(4):285-6 PMID: 11276195
  80. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway.
    J Biol Chem. 2001 Apr 6;276(14):11402-8 PMID: 11278366
  81. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.
    Nat Cell Biol. 2001 Apr;3(4):409-16 PMID: 11283615
  82. Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway.
    J Biol Chem. 2001 Feb 2;276(5):3650-9 PMID: 11062239
  83. Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin's disease.
    J Pathol. 2001 Jun;194(2):158-64 PMID: 11400143
  84. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway.
    Cancer Res. 2001 Jun 15;61(12):4797-808 PMID: 11406555
  85. The essential role of MEKK3 in TNF-induced NF-kappaB activation.
    Nat Immunol. 2001 Jul;2(7):620-4 PMID: 11429546
  86. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells.
    Oncogene. 2001 Jun 28;20(29):3888-96 PMID: 11439352
  87. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1.
    J Biol Chem. 2001 Jul 20;276(29):27322-8 PMID: 11350953
  88. NF-kappaB signals induce the expression of c-FLIP.
    Mol Cell Biol. 2001 Aug;21(16):5299-305 PMID: 11463813
  89. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment.
    J Immunol. 2001 Aug 1;167(3):1592-600 PMID: 11466381
  90. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway.
    Science. 2001 Aug 24;293(5534):1495-9 PMID: 11520989
  91. The INK4a/ARF network in tumour suppression.
    Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7 PMID: 11584300
  92. Beta-Arrestins: new roles in regulating heptahelical receptors' functions.
    Cell Signal. 2001 Oct;13(10):683-9 PMID: 11602178
  93. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.
    J Biol Chem. 2001 Nov 2;276(44):41424-34 PMID: 11518711
  94. The new melanoma staging system.
    Tumori. 2001 Jul-Aug;87(4):S64-8 PMID: 11693828
  95. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma.
    J Natl Cancer Inst. 2001 Nov 7;93(21):1638-43 PMID: 11698568
  96. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame.
    Cancer Res. 2001 Nov 15;61(22):8150-7 PMID: 11719444
  97. Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol.
    Mol Cell Biol. 2002 Oct;22(20):7158-67 PMID: 12242293
  98. BRAF and RAS mutations in human lung cancer and melanoma.
    Cancer Res. 2002 Dec 1;62(23):6997-7000 PMID: 12460918
  99. NF-kappaB signaling. Many roads lead to madrid.
    Cell. 2002 Nov 27;111(5):615-9 PMID: 12464174
  100. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy.
    Curr Cancer Drug Targets. 2004 Jun;4(4):327-36 PMID: 15180498
  101. Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1.
    Cancer Res. 2004 Jul 15;64(14):4858-69 PMID: 15256456
  102. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
    Oncogene. 2004 Aug 5;23(35):5968-77 PMID: 15195137
  103. B-RAF is a therapeutic target in melanoma.
    Oncogene. 2004 Aug 19;23(37):6292-8 PMID: 15208680
  104. Signaling to NF-kappaB.
    Genes Dev. 2004 Sep 15;18(18):2195-224 PMID: 15371334
  105. GPCR interacting proteins (GIP).
    Pharmacol Ther. 2004 Sep;103(3):203-21 PMID: 15464590
  106. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.
    Nature. 1984 May 31-Jun 6;309(5967):418-25 PMID: 6328312
  107. Characterization of autostimulatory and transforming growth factors from human melanoma cells.
    Cancer Res. 1985 Dec;45(12 Pt 1):6390-4 PMID: 3864531
  108. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
    Science. 1985 Dec 6;230(4730):1132-9 PMID: 2999974
  109. Model predicting survival in stage I melanoma based on tumor progression.
    J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904 PMID: 2593166
  110. The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency.
    Mol Cell Biol. 1991 Apr;11(4):2040-8 PMID: 1672440
  111. Cutaneous melanoma.
    N Engl J Med. 1991 Jul 18;325(3):171-82 PMID: 1805813
  112. Tumour progression and the nature of cancer.
    Br J Cancer. 1991 Oct;64(4):631-44 PMID: 1911211
  113. RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B.
    Mol Cell Biol. 1992 Feb;12(2):674-84 PMID: 1732739
  114. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma.
    J Immunol. 1992 Feb 15;148(4):1280-5 PMID: 1737940
  115. Cytogenetics of melanocytic tumors.
    J Invest Dermatol. 1993 Mar;100(3):254S-258S PMID: 8440899
  116. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.
    Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1746-50 PMID: 8383326
  117. Chemokine receptors: gateways to inflammation and infection.
    Nat Med. 1996 Nov;2(11):1174-8 PMID: 8898734
  118. Control of the ERK MAP kinase cascade by Ras and Raf.
    Cancer Surv. 1996;27:101-25 PMID: 8909797
  119. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.
    Mol Cell Biol. 1996 Dec;16(12):7098-108 PMID: 8943365
  120. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaB.
    Oncogene. 1999 Apr 22;18(16):2663-6 PMID: 10353611
  121. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.
    Mol Cell Biol. 1999 Aug;19(8):5785-99 PMID: 10409765
  122. P16 UV mutations in human skin epithelial tumors.
    Oncogene. 1999 Sep 23;18(39):5477-81 PMID: 10498902
  123. Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice.
    Melanoma Res. 1999 Aug;9(4):347-50 PMID: 10504052
  124. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin.
    Melanoma Res. 1999 Aug;9(4):383-7 PMID: 10504057
  125. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain.
    J Biol Chem. 1999 Oct 22;274(43):30353-6 PMID: 10521409
  126. Chemokine receptors and melanoma metastasis.
    J Dermatol Sci. 2004 Nov;36(2):71-8 PMID: 15519136
  127. Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively.
    J Biol Chem. 2004 Dec 10;279(50):52141-9 PMID: 15469934
  128. Regulation of gene expression in melanoma: new approaches for treatment.
    J Cell Biochem. 2005 Jan 1;94(1):25-38 PMID: 15523674
  129. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway.
    Oncogene. 2005 Jan 20;24(4):616-26 PMID: 15580309
  130. Additional Cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma.
    Int J Oncol. 2005 Mar;26(3):597-605 PMID: 15703813
  131. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
    Melanoma Res. 2005 Feb;15(1):21-8 PMID: 15714117
  132. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells.
    J Biol Chem. 2001 Nov 30;276(48):45098-105 PMID: 11571298
  133. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B.
    Pigment Cell Res. 2001 Dec;14(6):456-65 PMID: 11775058
  134. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B.
    J Biol Chem. 2002 Feb 8;277(6):3863-9 PMID: 11733537
  135. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies.
    Ann Oncol. 2001 Dec;12(12):1663-6 PMID: 11843241
  136. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells.
    J Biol Chem. 2002 Mar 8;277(10):7920-8 PMID: 11773061
  137. NFkappaB-dependent signaling pathways.
    Exp Hematol. 2002 Apr;30(4):285-96 PMID: 11937262
  138. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4.
    Nature. 2002 Apr 18;416(6882):750-6 PMID: 11923871
  139. Missing pieces in the NF-kappaB puzzle.
    Cell. 2002 Apr;109 Suppl:S81-96 PMID: 11983155
  140. Cyclin D1 is a candidate oncogene in cutaneous melanoma.
    Cancer Res. 2002 Jun 1;62(11):3200-6 PMID: 12036934
  141. Early stage (I, II, III) melanoma.
    Curr Treat Options Oncol. 2001 Jun;2(3):183-91 PMID: 12057118
  142. The role of chemokines in melanoma tumor growth and metastasis.
    J Invest Dermatol. 2002 Jun;118(6):915-22 PMID: 12060384
  143. Mutations of the BRAF gene in human cancer.
    Nature. 2002 Jun 27;417(6892):949-54 PMID: 12068308
  144. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma.
    Am J Pathol. 2002 Jul;161(1):125-34 PMID: 12107097
  145. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway.
    Clin Cancer Res. 2002 Jul;8(7):2369-77 PMID: 12114442
  146. Nf-kappa B, chemokine gene transcription and tumour growth.
    Nat Rev Immunol. 2002 Sep;2(9):664-74 PMID: 12209135
  147. Mutation and expression of the p53 gene in human malignant melanoma.
    Melanoma Res. 1994 Feb;4(1):35-45 PMID: 8032216
  148. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene.
    Cancer Res. 1994 Sep 1;54(17):4785-90 PMID: 8062279
  149. A set of inducible genes expressed by activated human monocytic and endothelial cells contain kappa B-like sites that specifically bind c-Rel-p65 heterodimers.
    J Biol Chem. 1994 Aug 19;269(33):20823-5 PMID: 8063696
  150. Activation of NF-kappa B in vivo is regulated by multiple phosphorylations.
    EMBO J. 1994 Oct 3;13(19):4597-607 PMID: 7925300
  151. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses.
    Cell. 1995 Jan 27;80(2):321-30 PMID: 7834752
  152. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family.
    Cell. 1995 Jan 27;80(2):331-40 PMID: 7834753
  153. Expression of relB is required for the development of thymic medulla and dendritic cells.
    Nature. 1995 Feb 9;373(6514):531-6 PMID: 7845467
  154. FAP-1: a protein tyrosine phosphatase that associates with Fas.
    Science. 1995 Apr 21;268(5209):411-5 PMID: 7536343
  155. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B.
    Nature. 1995 Jul 13;376(6536):167-70 PMID: 7603567
  156. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE).
    Int J Cancer. 1995 Aug 9;62(4):367-76 PMID: 7635560
  157. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40.
    Science. 1995 Sep 8;269(5229):1424-7 PMID: 7544915
  158. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.
    Cell. 1996 Jan 26;84(2):299-308 PMID: 8565075
  159. The NF-kappa B and I kappa B proteins: new discoveries and insights.
    Annu Rev Immunol. 1996;14:649-83 PMID: 8717528
  160. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death.
    Science. 1996 Nov 1;274(5288):782-4 PMID: 8864118
  161. Human melanocyte senescence and melanoma susceptibility genes.
    Oncogene. 2003 May 19;22(20):3063-9 PMID: 12789281
  162. PTEN signaling pathways in melanoma.
    Oncogene. 2003 May 19;22(20):3113-22 PMID: 12789288
  163. Death receptors and melanoma resistance to apoptosis.
    Oncogene. 2003 May 19;22(20):3152-61 PMID: 12789291
  164. Ocular melanoma: a review and the relationship to cutaneous melanoma.
    Arch Dermatol. 2003 Aug;139(8):1067-73 PMID: 12925397
  165. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma.
    J Am Acad Dermatol. 2003 Nov;49(5):865-72 PMID: 14576666
  166. Immune evasion by murine melanoma mediated through CC chemokine receptor-10.
    J Exp Med. 2003 Nov 3;198(9):1337-47 PMID: 14581607
  167. INK4/ARF germline alterations in pancreatic cancer patients.
    Ann Oncol. 2004 Jan;15(1):70-8 PMID: 14679123
  168. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
    Cancer Res. 2003 Dec 1;63(23):8132-7 PMID: 14678966
  169. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
    Oncogene. 2003 Dec 18;22(58):9217-24 PMID: 14681681
  170. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
    J Invest Dermatol. 2003 Nov;121(5):1160-2 PMID: 14708620
  171. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype.
    Clin Exp Metastasis. 2003;20(8):723-31 PMID: 14713106
  172. Metastatic malignant melanoma.
    Drugs Today (Barc). 2003;39 Suppl C:17-38 PMID: 14988744
  173. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies.
    Pigment Cell Res. 2004 Apr;17(2):173-80 PMID: 15016307
  174. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
    Cell. 2004 Mar 19;116(6):855-67 PMID: 15035987
  175. Estimating the relative risk of developing melanoma in INK4A carriers.
    Eur J Cancer Prev. 2004 Feb;13(1):65-70 PMID: 15075790
  176. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1.
    Oncogene. 2005 Feb 17;24(8):1423-33 PMID: 15608673
  177. The role of B-RAF in melanoma.
    Cancer Metastasis Rev. 2005 Jan;24(1):165-83 PMID: 15785879
  178. No Evidence for BRAF as a melanoma/nevus susceptibility gene.
    Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):913-8 PMID: 15824163
  179. Role of the CDKN2A locus in patients with multiple primary melanomas.
    J Clin Oncol. 2005 May 1;23(13):3043-51 PMID: 15860862
  180. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation.
    Mol Cell Biol. 2005 May;25(10):3886-95 PMID: 15870263
Article Info
Journal
Pigment cell research
Abbr.
Pigment Cell Res
ISSN
0893-5785
DOI
10.1111/j.1600-0749.2006.00304.x
Published
2006-04-00
Pages
112-24
Language
English
Region
Denmark
NLM ID
8800247
PMCID
PMC2668252
Subset
IM
Grants
BLRD VA · IK6 BX005225 · United States
NCI NIH HHS · R01 CA098807 · United States
NCI NIH HHS · R01 CA116021-03 · United States
NCI NIH HHS · R01 CA116021-02 · United States
NCI NIH HHS · CA 098807 · United States
NCI NIH HHS · T32 CA009592 · United States
NCI NIH HHS · R01 CA116021 · United States
NCI NIH HHS · R01 CA116021-01 · United States
NCI NIH HHS · CA 116021 · United States
External Links
PubMed source DOI: 10.1111/j.1600-0749.2006.00304.x PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2